The most substantial evidence comes from a clinical trial called IPATential150, which examined the combination of ipatasertib (an AKT inhibitor) and abiraterone (an androgen biosynthesis inhibitor) in patients with cancer that lacked PTEN expression. The gene discussed is PTEN; the disease is cancer.